Although the MAPK and PI3K/AKT cascades have been identified as the master signaling pathways controlling the prostate cancer progression, targeting these nodes in the signaling cascades individually typically involves a switch to the other pathway in a rescue strategy by cancer cells to overcome monotherapies [33–35]. The gene discussed is AKT1; the disease is cancer.